Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the pathogenesis of VKH disease is not well understood, an autoimmune T-cell response to a melanocyte-associated antigen is considered to be a cause of VKH disease. The complex immunological response to interferon and ribavirin may induce or exacerbate the autoimmune condition; however, VKH disease is a very rare complication associated with interferon therapy in chronic hepatitis C. We report a case of VKH disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C. (Korean J Hepatol 2011;17:61-65)
INTRODUCTION
Interferon combined with ribavirin is commonly used in treating chronic hepatitis C. Interferon sometimes results in common side effects such as flu-like symptoms, fatigue, myalgia, headache, and in rare but fatal ones such as depression, suppressed bone marrow, interstitial pneumonia, diabetes, or autoimmune diseases. 1 Vogt-Koyanagi-Harada (VKH) disease is a multi-systemic granulomatous inflammatory disease with ophthalmic involvement (uveitis and retinal detachment), ear and meningeal involvement (headache, tinnitus, and encephalomeningitis), and skin and hair change (vitiligo, alopecia, and poliosis). It is a very rare complication associated with the interferon treatments. 2 The mechanism of VKH disease has not been known yet, but it is presumed that interferon brings alterations to the immunological responses to melanocytes. 3 We report a case of VKH disease which occurred during pegylated interferon and ribavirin therapy for chronic hepatitis C.
CASE REPORT
A 58-year-old woman visited our hospital for evaluation of chronic hepatitis C. The patient was diagnosed as chronic hepatitis C 10 years ago, but had not received any treatment.
She had been taking amlodipine 5 mg for hypertension for 8 years. She had no history of alcohol consumption, smoking, or injection drug use. Dermatological, pulmonary, cardiac and neurological examinations were normal. On her first visit to our hospital, the liver function test and the complete blood cell count were normal, and the serologic tests for hepatitis A and B and HIV were negative. She was infected with hepatitis C virus (HCV) genotype 1b, and HCV RNA level was 3.8×10 6 copies/mL. There were no specific findings except for the hepatic cyst from abdominal CT scan. Liver biopsy was recommended to evaluate liver inflammation and A B prednisolone at a dose of 1 g for 3 days, followed by daily oral administration at a dose of 60 mg prednisolone were introduced. After 2 weeks of steroid therapy, her eyesight was getting better, and retinal detachment disappeared (Fig. 3B ).
Prednisolone was progressively tapered to 10 mg daily during next two months, but relapse occurred. Intravenous pulses of methylprednisolone followed by oral prednisolone were performed. The uveitis and visual acuity improved.
While the HCV RNA had not been detected during the treatment of pegylated interferon-α2b and ribavirin, serum HCV RNA level increased to 3.0×10 7 copies/mL after ceasing of interferon based therapy. Oral prednisolone was slowly tapered to 10 mg daily and no relapse occurred.
DISCUSSION
Most of ophthalmological complications occurring during interferon therapy are benign, transient, and characterized by interferon-related retinopathy. Incidence of interferon-related retinopathy such as hemorrhage and cotton wool spots vary from 6 to 13%. 4 The rate of these complications is reported to be higher in patients with diabetes or hypertension, but is not related with HCV genotypes, platelet counts or types or dose of interferon. 5 More than 90% of the retinal diseases during the interferon treatment occur within the first 8 weeks.
Therefore, the retinal test must be carefully implemented The pathophysiological mechanism of this disease is not obviously known, but it is presumed to be an autoimmune response of the type 1 helper T-cell (Th1) to antigens related with melanocytes. 9, 10 This can be supported by the fact that when lymphocytes of the patient with VKH are exposed to melanocytes, the lymphocytes proliferate significantly.
11
Cutaneous injury or viral infection may induce sensitization of melanocyte and may precipitate the VKH disease. And also, thyroid disease or rheumatoid arthritis can be associated with VKH disease. 12, 13 Interferon enhances lymphocyte cytotoxicity, reveals class I antigens of major histocompatibility complex, and differentiates antigen-presenting cells. It might also make people arthritis, and psoriasis. 14, 15 Indeed, there are a few case reports about VKH disease occurrence in the treatment combined with interferon and ribavirin for chronic hepatitis C. 16 The occurrence of VKH disease in patient with HCV infection before interferon therapy also arouses suspicion regarding the role of the HCV in the pathogenesis of the disease. 16 Molecular mimicry between viral antigens and melanocyte-related antigens could lead to VKH disease.
However, most reports about its occurrence during interferon treatment for chronic hepatitis C suggest that interferon therapy rather than HCV infection per se may play a role in the development of VKH.
17
In order to achieve successful outcome and to prevent complications associated with interferon, selection of patients for the treatment is most important. Generally, the ones who have persistently normal alanine aminotransferase (ALT) levels were not a good candidate for the treatment since individuals with persistently normal ALT values have significantly less liver fibrosis than whom that have abnormal ALT levels. 18 In this case, her liver function tests were normal on her first visit to our hospital, but levels of transaminase had been shown above than 40 IU/L several times in her family doctor's clinic. Therefore she was not a person who had persistently normal ALT levels, and was worried about progression of liver disease and wanted to treat chronic hepatitis C. Hence, we decided to start interferon and ribavirin therapy without confirm of liver histology.
The revised diagnostic criteria of VKH disease (Table 1) has been clarified. 16, 17 While five items must be satisfied to be diagnosed as a complete VKH disease, it is diagnosed as an incomplete VKH disease when four items including a symptom among neurologic or dermatological conditions are satisfied. The present patient had no vitiligo before the interferon therapy (Fig. 1A) , after 9 months of starting interferon therapy, about 5 cm sized patches of de-pigmentation were seen around both lateral side of her forehead symmetrically.
Thus the patient met the criteria for incomplete VKH disease. 
